Compare BIO-TECHNE Corp (TECH) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Verisign, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while Verisign, Inc. trades at $297.85 (market cap $26.60B). The key difference: Verisign, Inc. is far larger — about 2.3× BIO-TECHNE Corp's market cap, and Verisign, Inc. pays the higher dividend (1.1%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and Verisign, Inc. for 123 Days on average.
| TECH | VRSN | |
|---|---|---|
Market Cap | $11.37B | $26.60B |
Volume | 3,153,511 | 1,731,865 |
Sector | Health | Technology |
52-Week High | $72.61 | $310.00 |
52-Week Low | $43.31 | $211.49 |
Typical Hold Time | 63 Days | 123 Days |
Enterprise Value | $11.40B | $27.90B |
Dividend Yield | 0.44% | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
VeriSign (VRSN) trades at $297.79, up 1.6% with strong technical momentum and bullish moving averages. The company maintains robust fundamentals with 49.8% net margins and consistent revenue growth, though recent earnings show mixed quarterly performance. Positive sentiment is supported by institutional buying and a pending Q3 2026 earnings report, while legal challenges and insider selling present near-term risks.
Outlook remains positive with a $348 consensus price target offering 17% upside potential. Key catalysts include domain registration growth and AI-driven demand, balanced by antitrust litigation risks and competitive pressures. The stock presents a compelling opportunity for growth investors seeking stable cash flow generation in internet infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
